SCYNEXIS
SCYX
#8307
Rank
NZ$0.51 B
Marketcap
NZ$6.44
Share price
-5.81%
Change (1 day)
425.65%
Change (1 year)

P/E ratio for SCYNEXIS (SCYX)

P/E ratio as of July 2026 (TTM): -0.5670

According to SCYNEXIS's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.566964. At the end of 2025 the company had a P/E ratio of -0.4453.

P/E ratio history for SCYNEXIS from 2014 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025-0.445346.49%
2024-0.3040-252.67%
20230.1991-250.1%
2022-0.1327-78.98%
2021-0.6310257.1%
2020-0.176754.77%
2019-0.1142-52.99%
2018-0.2429-21.28%
2017-0.308522.24%
2016-0.2524-12.3%
2015-0.2878-77.15%
2014-1.26

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Galmed Pharmaceuticals
GLMD
-0.2781-50.95%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Catalyst Pharmaceuticals
CPRX
17.4-3,168.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Catalent
CTLT
-49.2 8,579.44%๐Ÿ‡บ๐Ÿ‡ธ USA
KemPharm
KMPH
-5.87 935.11%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.